The Medicare Evidence Development & Coverage Advisory Committee (MedCAC) convened today and representatives from organizations such as the American College of Radiology and the Lung Cancer Alliance went before the committee to contend for national Medicare coverage of low dose CT (LDCT) screening for patients who are at a high risk for lung cancer.

In the first trial of its kind, a new type of peptide receptor is being targeted in neuroendocrine tumor (NET) imaging, which could reveal previously hidden cancer, according to a study published April 17 in the Journal of Nuclear Medicine.

Data from multiple clinical trials for DaTscan (I-123 FP-CIT Ioflupane) using SPECT shows that the exam is very sensitive for detecting striatal dopaminergic deficits, according to a presentation during the American Academy of Neurology being held April 26 through May 3 in Philadelphia.

Breast cancer screening and treatment is still a work in progress. Debate continues over the optimal frequency of screening, which patient populations to target and how different supplemental screening modalities fit in. Whatever take you have on these issues, the top stories in women’s imaging over the last month should offer plenty to mull over.

The first markets for newly FDA-approved Vizamyl (F-18 flutemetamol), designated for ruling out Alzheimer’s disease and other dementias, were announced during the annual meeting of the American Academy of Neurology this week in Philadelphia, according to a statement from its producer, GE Healthcare.

Characteristics of the brain’s resting-state functional architecture are pertinent to understanding the relationship between the neural substrate and executive function in young patients with attention deficit hyperactivity disorder (ADHD), according to a study published on April 30 by Radiology. 

Siemens Healthcare has announced that the U.S. Food and Drug Administration (FDA) has cleared the SOMATOM Force computed tomography (CT) system -- the next generation in dual source CT.

A potential therapy targeting the misfolded proteins in neurodegenerative disease including Alzheimer;s, Parkinson’s and Huntington’s disease is edging closer to human trials, NeuroPhage Pharmaceuticals announced April 22.